Bristol Myers Squibb BMY and GSK PLC GSK are among the largest global biopharma companies with broad and diverse portfolios.

GSK is a leading biopharmaceutical company with a focus on vaccines and products for major diseases. GSK's drug line-up is safe and profitable, with competitors facing larger sales loss exposure due ...

GSK is shifting to specialty growth (HIV, oncology, asthma) with key launches and a deep late-stage pipeline—still ...

It’s been an upbeat week for GSK as it reported a trio of positive updates stemming from vaccines and oncology products. Most notable, perhaps, was the news that the British drugmaker took a step ...

LONDON (AP) — British pharmaceutical company GlaxoSmithKline says earnings from its core business rose 19 percent, driven by sales of vaccines and new products. Core operating profit, which excludes ...

LONDON/MUMBAI (Reuters) - Indian generics firm Lupin , some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being ...

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents ...

A new company, Haleon, now sells dozens of products from what was formerly GSK's huge consumer health division, which was spun off in 2022. The company pretends to be highly ethical in its website ...

Unknown litigation costs have cast a cloud over wide-moat GSK GSK since 2020, when the US Food and Drug Administration requested that Zantac be taken off the market. But earlier this month, GSK ...

LONDON/MUMBAI, July 22 (Reuters) - Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs ...